Identify. predict. act
Add Abbotts High Sensitive Troponin-I cardiac specific blood test to your patients' health check. And help change lives.
High Sensitive Troponin-I can help to more accurately identify elevated risk of a future cardiac event, even in apparently healthy individuals.
Abbott's High Sensitive Troponin-I (hsTnI) blood test can help to identify patients who are at high-risk or potentially at high-risk of heart attacks, heart failure or cardiovascular disease, including cardiovascular death, MI, coronary revascularization, heart failure, or ischemic stroke. The result, in conjunction with clinical and diagnostic findings, can then be used to prioritize the care of at-risk patients and develop a treatment plan that mitigates the risk of unfavorable outcomes.2,3
Troponin I is specific to the heart and therefore it can more accurately categorize patients' risk, in conjunction with other clinical and diagnostic findings, before they experience a cardiovascular event.1–3
There are a variety of cardiovascular (CV) risk prediction models currently available, however no other test is specific to the heart. These other models, which take into consideration the presence of CV risk factors, are indirect methods that pose challenges due to their:
Abbott's hsTnI can detect troponin, which is released when heart muscle is injured, even at low levels. Using the results from an hsTnI blood test can help you to more accurately stratify the risk of a future cardiac event in an asymptomatic individual into one of three categories:2,3
In conjunction with clinical and diagnostic findings, it enables you to better prioritize appropriate care for those at higher risk to help prevent adverse outcomes, and potentially avoid unnecessary investigations and treatments in those at lower risk.
Through this early cardiac risk identification model, long-term lifestyle changes and targeted treatments can be recommended to patients before a cardiac incident takes place.7 This helps you to empower patients to take control of their well-being by making healthy choices.
Abbott's hsTnI results, are to be applied to the
risk stratification table shown below:
Identify risk based on the addition of a cardiac specific test showing the presence of cardiac muscle injury. Assess which risk category (low/moderate/elevated) an individual falls into based on the corresponding troponin I level. An accompanying statement interpreting these results, may be provided.
Clinically assess the information provided by hsTnI in addition to classic risk factors and guideline-driven management of risk. Use your clinical judgement and adhere to recommended cardiovascular prevention guidelines to determine the standard of care appropriate for your patient based upon their level of risk.
Utilize the new heart-specific variable to motivate your patients to take action to make healthier living choices to improve their heart health.
Watch how assessing troponin I levels in the apparently healthy population can help identify a patient with an elevated risk of a future cardiac event with more accuracy.
Current risk-stratification tools such as Framingham, SCORE, and Lipid profile are not cardiac-specific and can be overly influenced by age. Abbott's hsTnI risk stratification blood test contains the protein troponin I, which is specific to the heart. This means it can more accurately categorize patients' risk when used in conjunction with clinical and diagnostic findings.6,8–11
Early detection to more accurately evaluate risk of future cardiac events, in conjunction with other clinical and diagnostic findings.6
Greater accuracy in identifying lower-risk patients, which may avoid unnecessary testing, treatments, and potential side effects.6
Potential to reduce the growing cost burden to the healthcare system by appropriately recategorizing at-risk patients.6
Abbott's hsTnI is not impacted by biotin interference.12
Find out more about how hsTnI can more accurately predict the risk of a future
cardiac event even in an apparently healthy population.
Cardiologists Professor Dr. Christoph Liebetrau and Associate Professor Dr. Till Keller from the Cardiac Center in Bad Nauheim, Germany discuss the significance of cardiac risk stratification with troponin I and possible areas of application.
Explore how High Sensitive Troponin may enable easier management of patients with suspect AMI.
Instill confidence in your cardiac care decision making with our comprehensive cardiac assay menu.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.